DMRA Price / Book | DAMORA THERAPEUTICS, INC.

Damora Therapeutics, Inc. Price/Book Ratio

The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.

Damora Therapeutics, Inc. price/book ratio for the quarter ending 2026-06-30 was 3.11, a 653.95% increase year-over-year.
Damora Therapeutics, Inc. price/book ratio for the quarter ending 2026-03-31 was 3.05, a 921.34% increase year-over-year.
Damora Therapeutics, Inc. price/book ratio for the quarter ending 2025-12-31 was 0.15, a 60.47% decline year-over-year.
Damora Therapeutics, Inc. price/book ratio for the quarter ending 2025-09-30 was 0.62, a 15.26% decline year-over-year.
Damora Therapeutics, Inc. price/book ratio for fiscal 2026 was 3.11.
Damora Therapeutics, Inc. price/book ratio for fiscal 2025 was 0.15, a 60.47% decline from fiscal 2024.
Damora Therapeutics, Inc. price/book ratio for fiscal 2024 was 0.39, a 35.93% decline from fiscal 2023.
Damora Therapeutics, Inc. price/book ratio for fiscal 2023 was 0.6, a 94.94% decline from fiscal 2022.

Available history: 2020-12-31 to 2026-06-30
Data captured: 2026-06-30

Historical Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	3.11	$1.6B	$516.06M
2026-03-31	3.05	$1.56B	$511.6M
2025-12-31	0.15	$36.75M	$240.38M
2025-09-30	0.62	$4.94M	$8.01M
2025-06-30	0.41	$4.52M	$10.95M
2025-03-31	0.3	$4.1M	$13.71M
2024-12-31	0.39	$6.12M	$15.83M
2024-09-30	0.73	$15.23M	$20.94M
2024-06-30	13.62	$321.38M	$23.59M
2024-03-31	18.78	$528.7M	$28.16M
2023-12-31	0.6	$19.52M	$32.33M
2023-09-30	13.06	$488.03M	$37.38M
2023-06-30	38.96	$1.7B	$43.7M
2023-03-31	25.38	$1.28B	$50.33M
2022-12-31	11.94	$737.51M	$61.75M
2022-09-30	16.62	$1.21B	$72.73M
2022-06-30	12.88	$1.1B	$85.07M
2022-03-31	13.71	$1.39B	$101.31M
2021-12-31	16.32	$1.91B	$117.22M
2021-09-30	17.49	$2.27B	$129.62M
2021-06-30	22.59	$3.2B	$141.43M
2021-03-31	25.15	$3.84B	$152.57M
2020-12-31	47.74	$7.9B	$165.49M

Annual Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	3.11	$1.6B	$516.06M
2025-12-31	0.15	$36.75M	$240.38M
2024-12-31	0.39	$6.12M	$15.83M
2023-12-31	0.6	$19.52M	$32.33M
2022-12-31	11.94	$737.51M	$61.75M
2021-12-31	16.32	$1.91B	$117.22M
2020-12-31	47.74	$7.9B	$165.49M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
HARROW, INC. (HROW)	United States	$1.240B	-42.77
Avalyn Pharma Inc. (AVLN)	United States	$1.267B
OPKO HEALTH, INC. (OPK)	United States	$1.220B	-15.59
LB PHARMACEUTICALS INC (LBRX)	United States	$1.220B	-10.87
First Tracks Biotherapeutics, Inc. (TRAX)	United States	$1.280B
Bicara Therapeutics Inc. (BCAX)	United States	$1.309B	-10.55
Jaguar Health, Inc. (JAGX)	United States	$1.184B
Latigo Biotherapeutics, Inc. (LTGO)	United States	$1.176B
Tyra Biosciences, Inc. (TYRA)	United States	$1.337B	-12.83
Kardigan, Inc. (KARD)	United States	$1.346B